Synchronous Overexpression of Epidermal Growth Factor Receptor and HER2-<b> <i>neu</i> </b> Protein Is a Predictor of Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer

2004136 citationsJournal Article

Authors

Amir Onn · The University of Texas MD Anderson Cancer Center

Arlene M. Correa · The University of Texas MD Anderson Cancer Center

Michael Z. Gilcrease · The University of Texas MD Anderson Cancer Center

Takeshi Isobe · The University of Texas MD Anderson Cancer Center

Erminia Massarelli · The University of Texas MD Anderson Cancer Center

Corazon D. Bucana · The University of Texas MD Anderson Cancer Center

Abstract

Synchronous overexpression of EGFR and HER2-neu at the protein level predicts increased recurrence risk and may predict decreased survival in patients with stage I NSCLC. This suggests that important interactions take place among the different members of the ErbB family during tumor development and suggests a method for choosing targeted therapy. A prospective study is planned.

Topics & Keywords

Lung Cancer Treatments and Mutations HER2/EGFR in Cancer Research Colorectal Cancer Treatments and Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 10, Issue 1, pp. 136-143

DOI: 10.1158/1078-0432.ccr-0373-3

Field-Weighted Citation Impact: 13.73